This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Pediatr Adolesc Med. 2001;155:199-200.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The study by Stevens et al¹ from the University of Rochester examines an important issue facing many pediatricians, neonatologists, and pulmonologists: the cost-effectiveness of immune globulin prophylaxis for respiratory syncytial virus (RSV) hospitalization. It is important in cost analyses for researchers, reviewers, and readers to carefully consider assumptions made since subsequent results may be strongly influenced by such assumptions. The authors carefully describe many of the cost assumptions made in this study. For example, effectiveness of immune globulin products in actual clinical practice was assumed to be equal to efficacy demonstrated in clinical trials, no drug wastage was assumed, overestimation of the true hospitalization rate for nonuniversity premature newborns was acknowledged, etc. The authors make 1 assumption that may not be justified, and should be clarified for readers since the resulting cost analyses would be strongly influenced. The issue is the assumed average weight of patients used in the RSV . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact and Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis for Kansas Medicaid's High-Risk Children
Shireman and Braman
Arch Pediatr Adolesc Med 2002;156:1251-1255.
ABSTRACT | FULL TEXT